Relugolix (TAK-385) possesses higher affinity and potent antagonistic activity for human (binding IC50=0.33 nM in the presence of serum) and monkey GnRH receptor (IC50=0.32 nM), but has low affinity for the rat GnRH receptor (IC50=9800 nM).
Relugolix (TAK-385) acts as an antagonist for human GnRH receptor in vivo and daily oral administration potently, continuously and reversibly suppresses the hypothalamic-pituitary-gonadal axis.
|Animal models||Six-week-old male hGNRHR-knock-in mice|
|Formulation||0.5% methylcellulose solution containing 6 mg/mL citric acid monohydrate|
|Dosages||3, 10 or 30 mg/kg|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO: ≥ 48 mg/mL|
 Nakata D, et al. Eur J Pharmacol. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.
|Related Estrogen Receptor Products|
Quinestrol is a synthetic estrogen that has the potential to be used in breast and prostate cancer related research.
Giredestrant (GDC-9545) is a potential "best-in-class" selective estrogen receptor inhibitor (SERD). Giredestrant can competitively bind with Estradiol in the ER ligand binding domain and induce conformational changes. Giredestrant has antitumor activity.
Zuclomiphene citrate is a cis isomer of clomiphene citrate. Zuclomiphene citrate has an anti-estrogen effect and inhibits the secretion of luteinizing hormone (LH) more than trans isomers. Zuclomiphene citrate is also an oral active cholesterol lowering agent.
27-Hydroxycholesterol is a selective estrogen receptor modulator, and it is also an agonist of the liver X receptor.
SAR439859 (Amcenestrant) is an orally active, nonsteroidal and selective degrader of estrogen receptor, it is also a potent antagonist of ER with EC50 of 0.2 nM for ERα degradation.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.